Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

June 3, 2021

Study Completion Date

June 24, 2021

Conditions

Healthy

Interventions

DRUG

Barcimiant

1 tablet contains 4 mg Barcitinib

DRUG

Olumiant (first dose)

1 tablet contains 4 mg Barcitinib

DRUG

Olumiant (second dose)

1 tablet contains 4 mg Barcitinib

Trial Locations (1)

Genuine Research Center GRC, Cairo